[PRE 14A] TMC the metals company Inc. Preliminary Proxy Statement
Form 4 filing for Clover Health Investments Corp. (CLOV) discloses three transactions by Jamie L. Reynoso, CEO – Medicare Advantage, on July 3 and July 7, 2025.
- Dispositions: 19,789 Class A shares sold on 7/3/25 at a weighted-average price of $2.58; 2,012 shares sold on 7/7/25 at $2.85. Both sales executed under a Rule 10b5-1 plan adopted 3/13/25.
- Withholding for taxes: 8,706 shares automatically withheld on 7/3/25 at $2.56 to satisfy tax obligations upon RSU vesting.
- Post-transaction ownership: Reynoso continues to hold 3,297,821 Class A shares directly.
- The RSU award that triggered the tax withholding vests quarterly through 1/3/27, subject to continued service.
No derivative security activity was reported. The transactions represent roughly 0.66 % of Reynoso’s stated post-filing stake, indicating a modest reduction in ownership.
Deposito del Modulo 4 per Clover Health Investments Corp. (CLOV) rivela tre operazioni effettuate da Jamie L. Reynoso, CEO – Medicare Advantage, il 3 e il 7 luglio 2025.
- Disposizioni: Vendita di 19.789 azioni di Classe A il 3/7/25 a un prezzo ponderato medio di 2,58 $; vendita di 2.012 azioni il 7/7/25 a 2,85 $. Entrambe le vendite sono state eseguite nell’ambito di un piano Rule 10b5-1 adottato il 13/3/25.
- Ritenuta fiscale: 8.706 azioni trattenute automaticamente il 3/7/25 a 2,56 $ per soddisfare gli obblighi fiscali legati alla maturazione delle RSU.
- Possesso post-transazione: Reynoso detiene ancora direttamente 3.297.821 azioni di Classe A.
- Il premio RSU che ha determinato la ritenuta fiscale matura trimestralmente fino al 3/1/27, subordinato al mantenimento del servizio.
Non è stata segnalata alcuna attività su strumenti derivati. Le operazioni rappresentano circa il 0,66 % della quota dichiarata da Reynoso dopo il deposito, indicando una riduzione modesta della proprietà.
Presentación del Formulario 4 para Clover Health Investments Corp. (CLOV) revela tres transacciones realizadas por Jamie L. Reynoso, CEO – Medicare Advantage, el 3 y 7 de julio de 2025.
- Disposiciones: Venta de 19,789 acciones Clase A el 3/7/25 a un precio promedio ponderado de $2.58; venta de 2,012 acciones el 7/7/25 a $2.85. Ambas ventas se ejecutaron bajo un plan Rule 10b5-1 adoptado el 13/3/25.
- Retención para impuestos: Se retuvieron automáticamente 8,706 acciones el 3/7/25 a $2.56 para cubrir obligaciones fiscales al momento de la consolidación de las RSU.
- Propiedad después de las transacciones: Reynoso continúa poseyendo directamente 3,297,821 acciones Clase A.
- El premio RSU que originó la retención fiscal se consolida trimestralmente hasta el 3/1/27, sujeto a la continuidad del servicio.
No se reportó actividad con valores derivados. Las transacciones representan aproximadamente el 0.66 % de la participación declarada por Reynoso tras la presentación, indicando una reducción modesta en la propiedad.
Clover Health Investments Corp. (CLOV)의 Form 4 제출은 2025년 7월 3일과 7월 7일에 Jamie L. Reynoso, Medicare Advantage CEO가 수행한 세 건의 거래를 공개합니다.
- 처분 내역: 2025년 7월 3일에 19,789주 Class A 주식을 가중 평균 가격 $2.58에 매도; 7월 7일에 2,012주를 $2.85에 매도. 두 거래 모두 2025년 3월 13일 채택된 Rule 10b5-1 계획에 따라 실행됨.
- 세금 원천징수: RSU 취득에 따른 세금 납부를 위해 7월 3일에 8,706주가 자동으로 원천징수되어 $2.56에 처리됨.
- 거래 후 소유 현황: Reynoso는 직접 3,297,821주의 Class A 주식을 계속 보유 중.
- 세금 원천징수를 유발한 RSU 보상은 지속적인 근무 조건 하에 2027년 1월 3일까지 분기별로 취득됨.
파생상품 증권 활동은 보고되지 않았으며, 이번 거래는 Reynoso의 신고 후 지분의 약 0.66%에 해당하여 소유 지분이 다소 감소했음을 나타냅니다.
Dépôt du Formulaire 4 pour Clover Health Investments Corp. (CLOV) révèle trois transactions effectuées par Jamie L. Reynoso, PDG – Medicare Advantage, les 3 et 7 juillet 2025.
- Dispositions : Vente de 19 789 actions de Classe A le 3/7/25 à un prix moyen pondéré de 2,58 $ ; vente de 2 012 actions le 7/7/25 à 2,85 $. Les deux ventes ont été réalisées dans le cadre d’un plan Rule 10b5-1 adopté le 13/3/25.
- Retenue pour impôts : 8 706 actions ont été automatiquement retenues le 3/7/25 à 2,56 $ pour satisfaire les obligations fiscales liées à l’acquisition des RSU.
- Possession après transaction : Reynoso détient toujours directement 3 297 821 actions de Classe A.
- La récompense RSU ayant déclenché la retenue fiscale est acquise trimestriellement jusqu’au 3/1/27, sous réserve de la poursuite du service.
Aucune activité sur des titres dérivés n’a été signalée. Les transactions représentent environ 0,66 % de la participation déclarée par Reynoso après le dépôt, indiquant une réduction modérée de la détention.
Formular 4 Einreichung für Clover Health Investments Corp. (CLOV) offenbart drei Transaktionen von Jamie L. Reynoso, CEO – Medicare Advantage, am 3. und 7. Juli 2025.
- Veräußerungen: Verkauf von 19.789 Class A Aktien am 3.7.25 zu einem gewichteten Durchschnittspreis von 2,58 $; Verkauf von 2.012 Aktien am 7.7.25 zu 2,85 $. Beide Verkäufe wurden im Rahmen eines Rule 10b5-1 Plans ausgeführt, der am 13.3.25 angenommen wurde.
- Steuerabzug: Am 3.7.25 wurden automatisch 8.706 Aktien zum Preis von 2,56 $ einbehalten, um Steuerverpflichtungen bei der RSU-Vesting zu erfüllen.
- Besitz nach der Transaktion: Reynoso hält weiterhin direkt 3.297.821 Class A Aktien.
- Die RSU-Zuteilung, die den Steuerabzug auslöste, vestet vierteljährlich bis zum 3.1.27, vorbehaltlich des fortgesetzten Dienstes.
Es wurde keine Aktivität mit derivativen Wertpapieren gemeldet. Die Transaktionen entsprechen etwa 0,66 % von Reynosos angegebenem Anteil nach der Einreichung, was auf eine moderate Reduzierung des Eigentums hinweist.
- High residual ownership: Jamie L. Reynoso still holds 3.3 million Class A shares, maintaining strong equity alignment.
- Insider selling activity: Disposition of 21,801 shares may be perceived negatively, though size is immaterial (<1% of holding).
Insights
TL;DR: Small insider sale (<1% stake) under 10b5-1 plan; minimal impact on valuation.
The combined 21,801-share sale, worth roughly $56k, is immaterial relative to Clover’s market capitalization and to Reynoso’s 3.3 million-share holding. Execution under a pre-planned 10b5-1 agreement limits signaling value. Tax-related share withholding is standard. Overall, the filing offers few clues about near-term fundamentals.
TL;DR: Governance-neutral event; adequate disclosure, large residual stake aligns incentives.
Use of a Rule 10b5-1 plan and detailed footnotes comply with SEC best practices, reducing concerns over opportunistic trading. Reynoso’s remaining 3.3 million shares preserve alignment with shareholders. No red flags emerge, but persistent small disposals could merit trend monitoring.
Deposito del Modulo 4 per Clover Health Investments Corp. (CLOV) rivela tre operazioni effettuate da Jamie L. Reynoso, CEO – Medicare Advantage, il 3 e il 7 luglio 2025.
- Disposizioni: Vendita di 19.789 azioni di Classe A il 3/7/25 a un prezzo ponderato medio di 2,58 $; vendita di 2.012 azioni il 7/7/25 a 2,85 $. Entrambe le vendite sono state eseguite nell’ambito di un piano Rule 10b5-1 adottato il 13/3/25.
- Ritenuta fiscale: 8.706 azioni trattenute automaticamente il 3/7/25 a 2,56 $ per soddisfare gli obblighi fiscali legati alla maturazione delle RSU.
- Possesso post-transazione: Reynoso detiene ancora direttamente 3.297.821 azioni di Classe A.
- Il premio RSU che ha determinato la ritenuta fiscale matura trimestralmente fino al 3/1/27, subordinato al mantenimento del servizio.
Non è stata segnalata alcuna attività su strumenti derivati. Le operazioni rappresentano circa il 0,66 % della quota dichiarata da Reynoso dopo il deposito, indicando una riduzione modesta della proprietà.
Presentación del Formulario 4 para Clover Health Investments Corp. (CLOV) revela tres transacciones realizadas por Jamie L. Reynoso, CEO – Medicare Advantage, el 3 y 7 de julio de 2025.
- Disposiciones: Venta de 19,789 acciones Clase A el 3/7/25 a un precio promedio ponderado de $2.58; venta de 2,012 acciones el 7/7/25 a $2.85. Ambas ventas se ejecutaron bajo un plan Rule 10b5-1 adoptado el 13/3/25.
- Retención para impuestos: Se retuvieron automáticamente 8,706 acciones el 3/7/25 a $2.56 para cubrir obligaciones fiscales al momento de la consolidación de las RSU.
- Propiedad después de las transacciones: Reynoso continúa poseyendo directamente 3,297,821 acciones Clase A.
- El premio RSU que originó la retención fiscal se consolida trimestralmente hasta el 3/1/27, sujeto a la continuidad del servicio.
No se reportó actividad con valores derivados. Las transacciones representan aproximadamente el 0.66 % de la participación declarada por Reynoso tras la presentación, indicando una reducción modesta en la propiedad.
Clover Health Investments Corp. (CLOV)의 Form 4 제출은 2025년 7월 3일과 7월 7일에 Jamie L. Reynoso, Medicare Advantage CEO가 수행한 세 건의 거래를 공개합니다.
- 처분 내역: 2025년 7월 3일에 19,789주 Class A 주식을 가중 평균 가격 $2.58에 매도; 7월 7일에 2,012주를 $2.85에 매도. 두 거래 모두 2025년 3월 13일 채택된 Rule 10b5-1 계획에 따라 실행됨.
- 세금 원천징수: RSU 취득에 따른 세금 납부를 위해 7월 3일에 8,706주가 자동으로 원천징수되어 $2.56에 처리됨.
- 거래 후 소유 현황: Reynoso는 직접 3,297,821주의 Class A 주식을 계속 보유 중.
- 세금 원천징수를 유발한 RSU 보상은 지속적인 근무 조건 하에 2027년 1월 3일까지 분기별로 취득됨.
파생상품 증권 활동은 보고되지 않았으며, 이번 거래는 Reynoso의 신고 후 지분의 약 0.66%에 해당하여 소유 지분이 다소 감소했음을 나타냅니다.
Dépôt du Formulaire 4 pour Clover Health Investments Corp. (CLOV) révèle trois transactions effectuées par Jamie L. Reynoso, PDG – Medicare Advantage, les 3 et 7 juillet 2025.
- Dispositions : Vente de 19 789 actions de Classe A le 3/7/25 à un prix moyen pondéré de 2,58 $ ; vente de 2 012 actions le 7/7/25 à 2,85 $. Les deux ventes ont été réalisées dans le cadre d’un plan Rule 10b5-1 adopté le 13/3/25.
- Retenue pour impôts : 8 706 actions ont été automatiquement retenues le 3/7/25 à 2,56 $ pour satisfaire les obligations fiscales liées à l’acquisition des RSU.
- Possession après transaction : Reynoso détient toujours directement 3 297 821 actions de Classe A.
- La récompense RSU ayant déclenché la retenue fiscale est acquise trimestriellement jusqu’au 3/1/27, sous réserve de la poursuite du service.
Aucune activité sur des titres dérivés n’a été signalée. Les transactions représentent environ 0,66 % de la participation déclarée par Reynoso après le dépôt, indiquant une réduction modérée de la détention.
Formular 4 Einreichung für Clover Health Investments Corp. (CLOV) offenbart drei Transaktionen von Jamie L. Reynoso, CEO – Medicare Advantage, am 3. und 7. Juli 2025.
- Veräußerungen: Verkauf von 19.789 Class A Aktien am 3.7.25 zu einem gewichteten Durchschnittspreis von 2,58 $; Verkauf von 2.012 Aktien am 7.7.25 zu 2,85 $. Beide Verkäufe wurden im Rahmen eines Rule 10b5-1 Plans ausgeführt, der am 13.3.25 angenommen wurde.
- Steuerabzug: Am 3.7.25 wurden automatisch 8.706 Aktien zum Preis von 2,56 $ einbehalten, um Steuerverpflichtungen bei der RSU-Vesting zu erfüllen.
- Besitz nach der Transaktion: Reynoso hält weiterhin direkt 3.297.821 Class A Aktien.
- Die RSU-Zuteilung, die den Steuerabzug auslöste, vestet vierteljährlich bis zum 3.1.27, vorbehaltlich des fortgesetzten Dienstes.
Es wurde keine Aktivität mit derivativen Wertpapieren gemeldet. Die Transaktionen entsprechen etwa 0,66 % von Reynosos angegebenem Anteil nach der Einreichung, was auf eine moderate Reduzierung des Eigentums hinweist.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
| | | |
TMC THE METALS COMPANY INC.
|
| | | |
| | | |
(Name of Registrant as Specified In Its Charter)
|
| | | |
| | | | | | | | |
| | | |
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
| | | |
![[MISSING IMAGE: lg_tmc-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001798562/000110465925066460/lg_tmc-bw.jpg)
![[MISSING IMAGE: sg_gerardbarron-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001798562/000110465925066460/sg_gerardbarron-bw.jpg)
Chairman & Chief Executive Officer
![[MISSING IMAGE: lg_tmc-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001798562/000110465925066460/lg_tmc-bw.jpg)
![[MISSING IMAGE: sg_gerardbarron-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001798562/000110465925066460/sg_gerardbarron-bw.jpg)
Chairman & Chief Executive Officer
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
| | | | 8 | | | | ||
|
EXECUTIVE OFFICER AND DIRECTOR COMPENSATION
|
| | | | 11 | | | | ||
|
EQUITY COMPENSATION PLAN INFORMATION
|
| | | | 24 | | | | ||
|
PROPOSAL NO. 1
|
| | | | 25 | | | | ||
|
APPROVAL OF AN ORDINARY RESOLUTION APPROVING AN AMENDMENT TO OUR 2021 INCENTIVE EQUITY PLAN TO INCREASE THE SHARE POOL FOR EQUITY INCENTIVE GRANTS UNDER THE PLAN
|
| | | | 25 | | | | ||
|
CODE OF BUSINESS CONDUCT AND ETHICS
|
| | | | 32 | | | | ||
|
OTHER MATTERS
|
| | | | 32 | | | | ||
|
SHAREHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR
|
| | | | 32 | | | | ||
|
APPENDIX A — 2021 INCENTIVE EQUITY PLAN, AS PROPOSED TO BE AMENDED
|
| | | | A-1 | | | | | |
1111 West Hastings Street, 15th Floor
Vancouver, British Columbia V6E 2J3
SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 28, 2025
THE SPECIAL MEETING TO BE HELD ON AUGUST 28, 2025
Name and Address of Beneficial Owner
|
| |
Number of
Common Shares(1) |
| |
Percentage
of Shares Beneficially Owned (%) |
| ||||||
Directors and Executive Officers: | | | | | | | | | | | | | |
Gerard Barron(2)
|
| | | | 22,794,289 | | | | | | 5.7% | | |
Craig Shesky(3)
|
| | | | 1,981,624 | | | | | | * | | |
Christian Madsbjerg(4)
|
| | | | 931,360 | | | | | | * | | |
Andrew C. Greig(5)
|
| | | | 5,015,913 | | | | | | 1.3% | | |
Andrew Hall(6)
|
| | | | 270,388 | | | | | | * | | |
Sheila Khama(7)
|
| | | | 298,633 | | | | | | * | | |
Andrei Karkar(8)
|
| | | | 65,850,382 | | | | | | 16.4% | | |
Erika Ilves(9)
|
| | | | 3,237,061 | | | | | | * | | |
Stephen Jurvetson(10)
|
| | | | 1,846,667 | | | | | | * | | |
Brendan May(11)
|
| | | | 129,864 | | | | | | * | | |
Michael Hess(12)
|
| | | | 6,666,666 | | | | | | 1.7% | | |
Alex Spiro(13)
|
| | | | — | | | | | | * | | |
All Directors and Executive Officers of the Company as a
Group (13 Individuals)(14) |
| | | | 110,773,681 | | | | | | 27.6% | | |
Five Percent Holders: | | | | | | | | | | | | | |
ERAS Capital LLC(15)
|
| | | | 64,868,211 | | | | | | 16.2% | | |
Allseas Group S.A(16)
|
| | | | 59,196,934 | | | | | | 14.8% | | |
Korea Zinc Company, Ltd.(17)
|
| | | | 26,491,557 | | | | | | 6.6% | | |
Compensation Element
|
| |
Primary Purpose
|
| |
Performance
Period |
| |
Details
|
|
Cash Compensation
|
| |||||||||
Base Salary | | | Reward for ongoing work performed, executive tenure and role | | | Ongoing | | | Provided in cash each pay period. | |
Short Term Incentive Plan (STIP) | | | Reinforce and drive short-term priorities and business results | | | 1 year | | |
Target award based on a percentage of salary.
|
|
| | | Recognize and reward corporate and individual performance | | | | | |
Awards may be earned from 0% to 100% of target based on achievement of pre- determined corporate short-term objectives that are aligned with our strategic plan as well as individual performance.
Awards are paid in cash upon the completion of the fiscal year; however, for 2024, 2023 and 2022, at the election of the Company, STIP awards were paid in immediately-vested RSUs to conserve operating cash.
|
|
Equity Compensation
|
| |||||||||
Long-term incentives (LTIP) | | |
Reinforce and drive long-term shareholder value
Retain executives over a multi-year period
Incentivize the achievement by management of multi-year performance goals
|
| | 3 years | | |
For 2024, 2023 and 2022, grants were in the form of RSUs that vest one-third per year over three years.
|
|
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($)(1) |
| |
Stock
Awards ($)(2) |
| |
All Other
Compensation ($)(3) |
| |
Total
($) |
| ||||||||||||||||||
Gerard Barron,
Chief Executive Officer |
| | | | 2024 | | | | | | 696,042 | | | | | | 574,234 | | | | | | 1,851,557 | | | | | | 69,604 | | | | | | 3,191,437 | | |
| | | 2023 | | | | | | 565,000 | | | | | | 508,500 | | | | | | 1,381,651 | | | | | | 150,500 | | | | | | 2,605,651 | | | ||
Craig Shesky
Chief Financial Officer |
| | | | 2024 | | | | | | 500,000 | | | | | | 412,500 | | | | | | 724,283 | | | | | | 50,000 | | | | | | 1,686,783 | | |
| | | 2023 | | | | | | 412,500 | | | | | | 309,375 | | | | | | 540,468 | | | | | | 41,250 | | | | | | 1,303,593 | | | ||
Erika Ilves
Chief Strategy Officer |
| | | | 2024 | | | | | | 487,000 | | | | | | 401,775 | | | | | | 724,283 | | | | | | 48,700 | | | | | | 1,661,758 | | |
| | | 2023 | | | | | | 433,333 | | | | | | 325,000 | | | | | | 540,468 | | | | | | 109,333 | | | | | | 1,408,134 | | |
| | | | | | | | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||
Name
|
| |
Effective
Grant Date |
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#)(1) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
shares or units of stock that have not vested (#)(2) |
| |
Market
value of shares or units of stock that have not vested ($)(3) |
| |||||||||||||||||||||
Gerard Barron
|
| | | | 9/9/2021 | | | | | | 3,473,586 | | | | | | — | | | | | | 0.65 | | | | | | 6/1/2028 | | | | | | — | | | | | | — | | |
| | | 9/9/2021 | | | | | | 604,458 | | | | | | 2,275,334 | | | | | | 0.65 | | | | | | 6/1/2028 | | | | | | — | | | | | | — | | | ||
| | | 3/20/2023 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 959,480(4) | | | | | | 1,074,618 | | | ||
| | | 3/20/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,276,936(4) | | | | | | 1,430,168 | | | ||
| | | 4/16/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000,000(5) | | | | | | 22,400,000 | | | ||
Erika Ilves
|
| | | | 9/9/2021 | | | | | | 1,099,968 | | | | | | — | | | | | | 0.65 | | | | | | 6/1/2028 | | | | | | — | | | | | | — | | |
| | | 9/9/2021 | | | | | | 262,109 | | | | | | 1,011,259 | | | | | | 0.65 | | | | | | 6/1/2028 | | | | | | — | | | | | | — | | | ||
| | | 3/20/2023 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 375,325(4) | | | | | | 420,364 | | | ||
| | | 3/20/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 499,505(4) | | | | | | 559,446 | | | ||
Craig Shesky
|
| | | | 9/9/2021 | | | | | | 405,251 | | | | | | — | | | | | | 8.64 | | | | | | 6/1/2028 | | | | | | — | | | | | | — | | |
| | | 9/9/2021 | | | | | | — | | | | | | 252,814 | | | | | | 0.65 | | | | | | 6/1/2028 | | | | | | — | | | | | | — | | | ||
| | | 3/20/2023 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 375,325(4) | | | | | | 420,364 | | | ||
| | | 3/20/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 499,505(4) | | | | | $ | 559,446 | | |
Position
|
| |
Retainer
|
| |||
Lead independent director
|
| | | $ | 30,000 | | |
Audit committee chairperson
|
| | | $ | 22,500 | | |
Audit committee member
|
| | | $ | 7,500 | | |
Compensation committee chairperson
|
| | | $ | 15,000 | | |
Compensation committee member
|
| | | $ | 5,000 | | |
Nominating and corporate governance committee chairperson
|
| | | $ | 15,000 | | |
Nominating and corporate governance committee member
|
| | | $ | 5,000 | | |
Sustainability and innovation committee chairperson
|
| | | $ | 15,000 | | |
Sustainability and innovation committee member
|
| | | $ | 5,000 | | |
Name
|
| |
Fees
Earned ($) |
| |
Stock
Awards ($)(1) |
| |
Total
($) |
| |||||||||
Andrew Hall
|
| | | $ | 106,236 | | | | | $ | 100,000 | | | | | $ | 206,236 | | |
Sheila Khama
|
| | | $ | 108,764 | | | | | $ | 100,000 | | | | | $ | 208,764 | | |
Andrei Karkar
|
| | | $ | 110,000 | | | | | $ | 100,000 | | | | | $ | 210,000 | | |
Amelia Kinahoi Siamomua
|
| | | $ | 95,000 | | | | | $ | 100,000 | | | | | $ | 195,000 | | |
Christian Madsbjerg
|
| | | $ | 114,368 | | | | | $ | 100,000 | | | | | $ | 214,368 | | |
Andrew Greig
|
| | | $ | 125,000 | | | | | $ | 100,000 | | | | | $ | 225,000 | | |
Brendan May
|
| | | $ | 61,154 | | | | | $ | 200,000(2) | | | | | $ | 261,154 | | |
Name
|
| |
Aggregate
Number of Shares Underlying Outstanding Options(1) |
| |
Number of
Shares or Units of Stock That Have Not Vested(2) |
| ||||||
Andrew Hall
|
| | | | | | | | | | 68,027 | | |
Sheila Khama
|
| | | | | | | | | | 68,027 | | |
Andrei Karkar
|
| | | | 769,020 | | | | | | 68,027 | | |
Amelia Kinahoi Siamomua
|
| | | | | | | | | | 68,027 | | |
Christian Madsbjerg
|
| | | | 716,916 | | | | | | 68,027 | | |
Andrew Greig
|
| | | | 716,916 | | | | | | 99,773 | | |
Brendan May
|
| | | | | | | | | | 136,054(3) | | |
| | |
(a)
|
| |
(b)
|
| |
(c)
|
| |||||||||
Plan category
|
| |
Number of securities
to be issued upon exercise of outstanding options, warrants and rights |
| |
Weighted-average
exercise price of outstanding options, warrants and rights |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
| |||||||||
Equity compensation plans approved by security holders
|
| | | | 62,198,105(1) | | | | | $ | 1.21(2) | | | | | | 10,648,622(3) | | |
Equity compensation plans not
approved by security holders |
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 62,198,105 | | | | | $ | 1.21 | | | | | | 10,648,622 | | |
APPROVAL OF AN ORDINARY RESOLUTION APPROVING AN AMENDMENT TO OUR 2021 INCENTIVE EQUITY PLAN TO INCREASE THE SHARE POOL FOR EQUITY INCENTIVE GRANTS UNDER THE PLAN
(Notice Item 1)
Name and Position or Group
|
| |
Options
|
| |
RSUs
|
| ||||||
Gerard Barron, Chairman and Chief Executive Officer(1)
|
| | | | — | | | | | | 26,351,748 | | |
Craig Shesky, Chief Financial Officer
|
| | | | — | | | | | | 2,668,219 | | |
Erika Ilves, Chief Strategy Officer
|
| | | | — | | | | | | 2,737,277 | | |
All current executive officers as a group
|
| | | | — | | | | | | 33,641,823 | | |
All current directors who are not executive officers as a group
|
| | | | 3,440,000 | | | | | | 1,904,226 | | |
All employees, including all current officers who are not executive officers, as a group
|
| | | | 750,000 | | | | | | 18,685,098 | | |
Name and Position or Group
|
| |
Options(1)
|
| |
RSUs(1)
|
| ||||||
Gerard Barron, Chairman and Chief Executive Officer
|
| | | | — | | | | | | — | | |
Craig Shesky, Chief Financial Officer
|
| | | | — | | | | | | — | | |
Erika Ilves, Chief Strategy Officer
|
| | | | — | | | | | | — | | |
All current executive officers as a group
|
| | | | — | | | | | | — | | |
Michael Hess, director(2)
|
| | | | 5,000,000 | | | | | | 7,737,530 | | |
Alex Spiro, director(3)
|
| | | | — | | | | | | 1,750,000 | | |
All current directors who are not executive officers as a group(4)
|
| | | | 5,000,000 | | | | | | 9,487,530 | | |
Brian Paes-Braga, consultant(5)
|
| | | | 1,500,000 | | | | | | 2,428,147 | | |
All employees, including all current officers who are not executive officers, as
a group |
| | | | — | | | | | | — | | |
1111 West Hastings Street, 15th Floor
Vancouver, British Columbia V6E 2J3
July 18, 2025
(As amended by the Board of Directors through July 8, 2025)
2021 INCENTIVE EQUITY PLAN
Terms of Grant of Options to United States Employees
U.S. SUB-PLAN TO THE
TMC THE METALS COMPANY INC.
2021 INCENTIVE EQUITY PLAN
![[MISSING IMAGE: px_25tmcthemetal1pg01-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001798562/000110465925066460/px_25tmcthemetal1pg01-bw.jpg)
![[MISSING IMAGE: px_25tmcthemetal1pg02-bw.jpg]](https://www.sec.gov/Archives/edgar/data/0001798562/000110465925066460/px_25tmcthemetal1pg02-bw.jpg)